New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
10:03 EDTLLY, ONNN, VIPS, WWWW, NKE, HAR, ALGT, CACI, GEVA, YELP, MNK, EL, ARMH, LG, PAL, FEYE, WBC, HUBGOn The Fly: Analyst Upgrade Summary
ARM Holdings (ARMH) upgraded to Market Perform from Underperform at Bernstein... Allegiant Travel (ALGT) upgraded to Buy from Hold at Deutsche Bank... Eli Lilly (LLY) upgraded to Market Perform from Underperform at BMO Capital... Estee Lauder (EL) upgraded to Outperform from Market Perform at Bernstein... Harman (HAR) upgraded to Strong Buy from Outperform at Raymond James...Hub Group (HUBG) upgraded to Buy from Hold at BB&T... Mallinckrodt (MNK) upgraded to Outperform from Market Perform at BMO Capital... Nike (NKE) upgraded to Buy from Hold at Stifel... S Ecology (ECOL) upgraded to Buy from Hold at KeyBanc... WABCO (WBC) upgraded to Conviction Buy from Buy at Goldman... Yelp (YELP) upgraded to Buy from Neutral at SunTrust... Web.com (WWWW) upgraded to Buy from Hold at Craig-Hallum... FireEye (FEYE) upgraded at Wedbush... Synageva (GEVA) upgraded at Wedbush... Vipshop (VIPS) upgraded to Outperform from Neutral at Credit Suisse... North American Palladium (PAL) upgraded to Sector Performer at CIBC... CACI International (CACI) upgraded to Outperform from Underperform at Raymond James... ON Semiconductor (ONNN) upgraded to Buy from Neutral at MKM Partners... Laclede (LG) upgraded to Buy from Hold at Stifel.
News For ARMH;ALGT;LLY;EL;HAR;HUBG;MNK;NKE;WBC;YELP;WWWW;FEYE;GEVA;VIPS;PAL;CACI;ONNN;LG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
March 19, 2015
08:08 EDTLLYEli Lilly and Hanmi sign license and collaboration agreement
Subscribe for More Information
08:08 EDTNKENike historically hits earnings, but guidance, valuation could weigh, WSJ says
Subscribe for More Information
March 18, 2015
12:48 EDTLLYFly Watch: Biogen predicted to report strong Alzheimer's data this Friday
Subscribe for More Information
10:48 EDTARMHCadence, ARM announce strategic IP interoperability agreement
Subscribe for More Information
07:59 EDTNKENike March volatility elevated into Q3 and outlook
Nike March call option implied volatility is at 69, April is at 28, May is at 23, July is at 22; compared to its 26-week average of 23 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on March 19.
07:46 EDTLLYLilly Roche would have upbeat read through from strong BIIB data, says Bernstein
Bernstein notes that the data for Biogen's (BIIB) Alzheimer's treatment, due to be released on Friday, is widely expected to be positive. The firm thinks that positive data would boost the outlook for similar Alzheimer's drugs being developed by Eli Lilly (LLY) and Roche (RHHBY), since consensus estimates for those drugs are low. The firm keeps Outperform ratings on Eli Lilly and Roche.
March 16, 2015
12:56 EDTCACIIBM protest of Army contract an incremental negative for CACI, says Maxim
According to a Washington Technology article, IBM (IBM) successfully protested a $158M Army-payroll contract awarded to CACI (CACI). Maxim expects the contract to be re-evaluated and for CACI to still prevail and win, but the revenue ramp will take longer than previously anticipated. The firm rates CACI a Buy with a $101 price target.
12:54 EDTCACIContract awarded to CACI protested by IBM, Washington Technology reports
A $158M Army payroll and personnel contract that was awarded to CACI (CACI) has been successfully protested by IBM (IBM) and the contract has been dismissed, Washington Technology reports. Reference Link
11:48 EDTNKEadidas won't renew contract with NBA after 2016-17 season, ESPN reports
Subscribe for More Information
11:17 EDTFEYEFireEye call activity attributed to takeover chatter
Subscribe for More Information
11:02 EDTFEYERumor: FireEye strength attributed to takeover speculation
Shares of FireEye (FEYE) are moving higher on speculation Cisco (CSCO) may acquire the company.
10:49 EDTNKENike March volatility increases into Q3 and outlook
Subscribe for More Information
10:02 EDTALGTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:14 EDTALGTAllegiant Travel downgraded to Market Perform at Raymond James
As previously reported, Raymond James downgraded Allegiant Travel to Market Perform from Outperform due to low upside potential. The firm does not recommend selling the stock, as domestic demand remains healthy and further upside to estimates exists if fuel prices remain lower for longer than forecast.
08:02 EDTCACICACI awarded two task order contracts totaling $86M
Subscribe for More Information
08:01 EDTONNNTranspohorm and ON Semiconductor announce start of production of GaN devices
Subscribe for More Information
07:27 EDTLLYBiodel BIOD-961 Phase 1 clinical trial meets primary efficacy endpoint
Biodel (BIOD) announced positive preliminary results from Study 6-101, a Phase 1 clinical trial comparing Biodel's lyophilized glucagon formulation BIOD-961, designed for use in a proprietary Glucagon Emergency Management, or GEM, auto-reconstitution device, to Eli Lilly's (LLY) Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen HypoKit, which are marketed for the treatment of severe hypoglycemia. Study 6-101 was a randomized, single-center, double blind, six-period cross over study in 15 healthy volunteers who received each glucagon administered subcutaneously, or SC, and intramuscularly, or IM, in a randomized treatment sequence. The objectives of the study were to compare the pharmacokinetic, or PK, profiles, the pharmacodynamic, or PD, glucose, responses, and the PK/PD relationships of IM and SC dosing, as well as to assess safety profiles of the three test glucagons. Study 6-101 was a Phase 1 randomized, single-center, double blind, six-period cross over study designed to evaluate the PK and PD profiles of BIOD-961 compared to marketed glucagon formulations manufactured by Eli Lilly and Novo Nordisk. BIOD-961 is a lyophilized glucagon formulation designed for use in the GEM auto-reconstitution device. On six separate dosing days, each subject received 1 mg of one of the test glucagons delivered either SC or IM. Fifteen normal, healthy subjects were randomized into the study and ten completed all dosings. The objectives of the study were to compare the PK profiles, the PD responses, and the PK/PD relationships of IM and SC dosing, as well as to assess safety profiles of the three test glucagons. These data will facilitate selection of an appropriate marketed glucagon to use as a comparator in the planned pivotal study, in which the primary efficacy endpoint for approval is to demonstrate PK and PD bioequivalence of BIOD-961 to one of the marketed comparators.
07:24 EDTNKENike has solid global demand ahead but FX a headwind, says Credit Suisse
Subscribe for More Information
07:09 EDTALGTAllegiant Travel downgraded to Market Perform from Outperform at Raymond James
06:32 EDTHARDelphi Automotive Harman infotainment revenue can jump, says Wells Fargo
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use